Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9152W HIGH $9.48
Volume
451.49 K
Value Traded
1.17 M
Short % Float
14.96%
Days to Cover
4.8
-10.1%Week
-11.39%1 Month
+38.39%3 Month
+136.1%6 Month
-81.23%5 Year
-81.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
396.21 M
EPS (TTM)
-0.31
P/E Ratio
-
Ent. Value
391.99 M
Total Shares
53.58 M
Float Shares
10.93 M
Insiders
79.65%
Institutions
16.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TKNO Catalyst Timeline
Dated clinical, regulatory and corporate events for Alpha Teknova, Inc.
Past FDA Catalysts and PDUFA Decisions
How TKNO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Alpha Teknova, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TKNO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DEMSKI MARTHA JDirector | Other | -12,000 | $0.00 | 07/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TKNO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 68.78 K | 14.01 K |
TKNO Institutional Ownership Trends
TKNO Short Interest
Shares sold short, counted twice a month.
14.96%
Short % of Float
of tradable shares sold short
1.6M
Shares Sold Short
+3.5% vs prior count
4.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
339.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TKNO ranks across every disease it competes in
Competitive Position is a premium feature
See how TKNO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTKNO News
TKNO▼ -15.4%today
Teknova Announces Proposed Public Offering of Common Stock
Teknova announced a public offering of its common stock, with plans to grant underwriters a 30-day option for additional shares. The company aims to use the proceeds for general corporate purposes, including potential debt repayment and investments in complementary businesses. The offering is subject to market conditions and is detailed in a prospectus to be filed with the SEC.
Read more →TKNO▼ -15.4%today
Teknova Announces Preliminary Third Quarter Financial Results
Teknova reported preliminary financial results for Q3 2026, estimating revenue between $12.5 million and $12.7 million. The gross margin is projected to be between 36.0% and 38.0%, showing significant improvement from the previous year. However, Adjusted EBITDA remains negative, indicating ongoing financial challenges.
Read more →TKNOTeknova to Report Second Quarter 2026 Financial Results on August 5, 2026
Teknova announced it will report its financial results for Q2 2026 on August 5, 2026. The company will host a webcast and conference call at 6:00 p.m. ET on the same day. This event aims to inform stakeholders about its financial performance and ongoing innovations in critical reagents.
Read more →TKNOAlpha Teknova Reports First Quarter 2026 Financial Results
Teknova has reported its financial results for the first quarter of 2026, achieving a total revenue of $11.1 million, which is a 13% increase from the previous year. The company has seen significant growth in its Clinical Solutions segment, with an 85% rise in revenue. Additionally, Teknova reaffirms its 2026 revenue guidance, projecting total revenue to be between $42 million and $44 million while also managing its expenses effectively.
Read more →TKNOTeknova to Report First Quarter 2026 Financial Results on May 6, 2026
Teknova has announced it will report its financial results for Q1 2026 on May 6, 2026. The report will be followed by a webcast and conference call at 6:00 p.m. Eastern Time. The company specializes in producing critical reagents for the life sciences sector, aiding in the development of therapies and diagnostics.
Read more →TKNO▲ +13.2%on this news
Teknova Reports Fourth Quarter and Full Year 2025 Financial Results
Teknova reported a 7% increase in total revenue for 2025, reaching $40.5 million. The company also noted a significant growth in Clinical Solutions revenue, which rose by 47% in the fourth quarter. Looking ahead, Teknova projects revenue of $42-44 million for 2026 and aims to achieve positive Adjusted EBITDA by the end of 2027, despite a net loss reported for the fourth quarter.
Read more →TKNOTeknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Teknova, a producer of critical reagents, will announce its financial results for Q4 and the full year of 2025 on February 26, 2026. The announcement will be followed by a webcast and conference call at 5:30 p.m. ET. This event aims to provide insights into the company's performance and future outlook.
Read more →TKNOTeknova Reports Third Quarter 2025 Financial Results
Teknova reported a total revenue of $10.5 million for Q3 2025, marking a 9% increase from the previous year. The company achieved its fifth consecutive quarter of revenue growth, driven by a rise in Lab Essentials sales. However, Clinical Solutions revenue saw a decline of 13%. Teknova reaffirmed its revenue guidance for 2025, expecting total revenue between $39 million and $42 million.
Read more →TKNOAlpha Teknova Reports Second Quarter 2025 Financial Results
Teknova reported a total revenue of $10.3 million for the second quarter of 2025, reflecting a 7% increase from the previous year and marking four consecutive quarters of growth. The company's gross margin improved significantly, driven by manufacturing efficiencies. Despite these positive financial metrics, Teknova still reported a net loss of $3.6 million and negative free cash flow. However, management remains optimistic about their 2025 outlook, reaffirming revenue guidance and showing confidence in continued operational advancements.
Read more →TKNO▲ +6.3%on this news
Alpha Teknova Reports First Quarter 2025 Financial Results
Teknova reported a revenue increase of 5% in Q1 2025, totaling $9.8 million, and reaffirmed its 2025 revenue guidance of $39-42 million. The company launched its proprietary PluriFreezeTM cryopreservation system in collaboration with Pluristyx, expanding its cell therapy product portfolio. Despite these achievements, Teknova faced a 32% decline in Clinical Solutions revenue and reported a net loss of $4.6 million during the quarter. Improvements in gross margins and operational efficiencies were noted as positive developments.
Read more →TKNOTeknova to Report First Quarter 2025 Financial Results on May 8, 2025
Teknova will report its financial results for Q1 2025 on May 8, 2025. The announcement includes details about a webcast and conference call for investors. The company emphasizes its role in producing critical reagents for novel therapies and diagnostics. Teknova has been innovating since 1996 and offers customizable solutions.
Read more →TKNOTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies
Teknova and Pluristyx have launched the PluriFreeze cryopreservation system, available exclusively from Teknova. This innovative system is designed to streamline the development of allogeneic cell therapies, featuring a synthetic, animal-origin-free formulation. The collaboration allows for wider access to high-quality biopreservation reagents, enhancing the workflow for cell therapy developers.
Read more →TKNOTeknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies
Teknova and Pluristyx have announced a collaboration to produce and commercialize the PluriFreeze product line, which is designed to enhance the manufacturing of allogeneic cell therapies. Teknova will serve as the exclusive manufacturer and distributor in the U.S. and Canada. The partnership aims to simplify the scale-up process for cell therapy developers. Further details will be revealed at the upcoming BioProcess International West conference.
Read more →TKNOAlpha Teknova Reports Fourth Quarter and Full Year 2024 Financial Results
Teknova reported financial results for the fourth quarter and full year 2024, revealing a 3% increase in total annual revenue to $37.7 million, with fourth quarter revenue rising 18% year-over-year. The company also achieved significant growth in its Clinical Solutions customer base, highlighting successful customer acquisition strategies. Despite the positive revenue growth, Teknova reported a net loss of $5.7 million for the fourth quarter, although this was an improvement from a larger loss in the previous year. Looking ahead, Teknova forecasts revenue of $39-42 million for 2025.
Read more →TKNOTeknova Reports Third Quarter 2024 Financial Results Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior year Company lowers 2024 total free cash outflow outlook to less than $16 million
Teknova reported its third quarter 2024 financial results, revealing a total revenue of $9.6 million, a 17% increase compared to the previous year. The company has lowered its anticipated free cash outflow for 2024 to under $16 million, indicating improved cash flow management. Despite the positive revenue growth, gross profit suffered a decline due to non-recurring charges related to inventory disposal. Teknova maintains its revenue guidance for the year, projecting a total revenue between $35 million and $38 million.
Read more →TKNOTeknova Reports Second Quarter 2024 Financial Results Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-Tek SM
Teknova reported its financial results for the second quarter of 2024, revealing a total revenue of $9.6 million, which is a 3% increase sequentially but a 17% decrease from the same quarter last year. The company successfully raised $15.4 million in equity capital, providing improved liquidity for future operations. Despite a 57% drop in Clinical Solutions revenue, Teknova has launched two new offerings aimed at enhancing product customization for customers. The company maintains its full-year 2024 revenue guidance of $35-38 million.
Read more →TKNOTeknova Announces $15.4 Million Private Placement
Teknova has announced a definitive agreement to issue and sell 12,385,883 shares of its common stock in a private placement, expected to yield approximately $15.4 million in gross proceeds. The private placement is set to close around July 12, 2024, pending customary conditions. Teknova intends to utilize the net proceeds for general corporate purposes and plans to file an initial registration statement with the SEC covering the resale of shares from this placement. However, the transaction carries risks related to SEC registration and fluctuating market conditions.
Read more →TKNO▼ -11.7%on this news
Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38
Teknova has provided a strategic business update along with preliminary financial results for Q2 2024, reporting total revenue in the range of $9.4 to $9.6 million. The company reaffirms its revenue guidance of $35-38 million for the full year, although Q2 2024 revenue reflects a decline compared to Q2 2023, adjusted figures indicate a slight increase in revenue. Notably, the company has expanded its Clinical Solutions customer base and improved manufacturing processes. Teknova aims for less than $18 million in Free Cash Outflow for 2024 as part of its financial management strategy.
Read more →TKNOTeknova Reports First Quarter 2024 Financial Results First quarter 2024 total revenue was $9.3 million, up 2% from prior year Launch of Build-Tek TM Custom Configurator Company reaffirms 2024 revenue guidance of $35-38 m
Teknova reported a 2% increase in total revenue for Q1 2024, reaching $9.3 million. The company successfully launched the Build-Tek™ Custom Configurator, designed for rapid buffer formulation. Despite a positive revenue outlook, Teknova experienced a decrease in gross profit and reported a net loss of $8.1 million. The company reiterated its revenue guidance for the full year, projecting between $35 million and $38 million.
Read more →TKNO▲ +6%on this news
Teknova Reports Fourth Quarter and Full Year 2023 Financial Results Full year 2023 total revenue was $36.7 million, down 11% year-over-year Achieved 36% annual growth in the number of Clinical Solutions customers in 2023
Teknova reported its financial results for the fourth quarter and full year 2023, showing a total revenue of $36.7 million, a decline of 11% compared to the prior year. Despite the revenue decrease, the company achieved a 36% growth in its Clinical Solutions customer base and improved its operating expense situation through cost-reduction measures. Looking forward, Teknova estimates its total revenue for 2024 to be between $35 million and $38 million, alongside anticipated free cash outflow of less than $18 million. However, the year also saw significant impairments and a net loss of $36.8 million.
Read more →About Alpha Teknova, Inc.
Headquarters2451 BERT DRIVE, HOLLISTER, CA, 95023
BIOPHARMAWATCH ELITE PLUS
Trade the next TKNO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime